Article
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature - 22 Feb 2018
Mariathasan Sanjeev, Turley Shannon J, Nickles Dorothee, Castiglioni Alessandra, Yuen Kobe, Wang Yulei, Kadel Edward E, Koeppen Hartmut, Astarita Jillian L, Cubas Rafael, Jhunjhunwala Suchit, Banchereau Romain, Yang Yagai, Guan Yinghui, Chalouni Cecile, Ziai James, Şenbabaoğlu Yasin, Santoro Stephen, Sheinson Daniel, Hung Jeffrey, Giltnane Jennifer M, Pierce Andrew A, Mesh Kathryn, Lianoglou Steve, Riegler Johannes, Carano Richard A D, Eriksson Pontus, Höglund Mattias, Somarriba Loan, Halligan Daniel L, van der Heijden Michiel S, Loriot Yohann, Rosenberg Jonathan E, Fong Lawrence, Mellman Ira, Chen Daniel S, Green Marjorie, Derleth Christina, Fine Gregg D, Hegde Priti S, Bourgon Richard, Powles Thomas
Abstract excerpt
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.